Fuan Pharmaceutical (Group) Co., Ltd. (300194.SZ)
CNY 4.11
(2.49%)
CNY 4.11
(2.49%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 528.99 Million CNY | 22.48% |
| 2022 | 340.61 Million CNY | 2.61% |
| 2021 | -409.89 Million CNY | 7.77% |
| 2020 | 407.06 Million CNY | -15.25% |
| 2019 | 473.14 Million CNY | 8.74% |
| 2018 | -186.79 Million CNY | -8.83% |
| 2017 | 483.35 Million CNY | 22.28% |
| 2016 | 391.28 Million CNY | 123.92% |
| 2015 | 170.4 Million CNY | 66.53% |
| 2014 | 100.57 Million CNY | 25.51% |
| 2013 | 79.44 Million CNY | -37.53% |
| 2012 | 134.18 Million CNY | 3.33% |
| 2011 | 130.47 Million CNY | -17.99% |
| 2010 | 159.58 Million CNY | 32.74% |
| 2009 | 122.26 Million CNY | 86.24% |
| 2008 | 63.01 Million CNY | 390.64% |
| 2007 | 12.73 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 112.73 Million CNY | -28.4% |
| 2024 Q3 | 102.43 Million CNY | -4.98% |
| 2024 Q1 | 152.37 Million CNY | 593.25% |
| 2023 Q3 | 106.74 Million CNY | 25.5% |
| 2023 Q1 | 112.92 Million CNY | 28.88% |
| 2023 FY | - CNY | 22.48% |
| 2023 Q4 | 41.38 Million CNY | -61.23% |
| 2023 Q2 | 85.05 Million CNY | -24.68% |
| 2022 Q1 | 48.26 Million CNY | -6.43% |
| 2022 Q4 | 87.62 Million CNY | 31.79% |
| 2022 Q2 | 66.46 Million CNY | 37.71% |
| 2022 FY | - CNY | 2.61% |
| 2022 Q3 | 66.48 Million CNY | 0.03% |
| 2021 Q1 | 74.52 Million CNY | 313.24% |
| 2021 Q3 | 85.62 Million CNY | 53.65% |
| 2021 Q4 | 51.58 Million CNY | -39.75% |
| 2021 FY | - CNY | 7.77% |
| 2021 Q2 | 55.72 Million CNY | -25.23% |
| 2020 Q4 | 18.03 Million CNY | -77.29% |
| 2020 Q3 | 79.41 Million CNY | 2.32% |
| 2020 Q2 | 77.61 Million CNY | -3.41% |
| 2020 Q1 | 80.35 Million CNY | 24.26% |
| 2020 FY | - CNY | -15.25% |
| 2019 FY | - CNY | 8.74% |
| 2019 Q4 | 64.66 Million CNY | -26.92% |
| 2019 Q3 | 88.49 Million CNY | -11.11% |
| 2019 Q2 | 99.55 Million CNY | 12.01% |
| 2019 Q1 | 88.87 Million CNY | 232.51% |
| 2018 Q3 | 72.27 Million CNY | -27.49% |
| 2018 FY | - CNY | -8.83% |
| 2018 Q1 | 106.2 Million CNY | 77.85% |
| 2018 Q2 | 99.67 Million CNY | -6.15% |
| 2018 Q4 | 26.73 Million CNY | -63.02% |
| 2017 FY | - CNY | 22.28% |
| 2017 Q2 | 134.4 Million CNY | 42.48% |
| 2017 Q4 | 59.71 Million CNY | 0.0% |
| 2017 Q1 | 94.33 Million CNY | 10.46% |
| 2017 Q3 | 59.71 Million CNY | -55.57% |
| 2016 Q3 | 90.48 Million CNY | 27.67% |
| 2016 FY | - CNY | 123.92% |
| 2016 Q4 | 85.4 Million CNY | -5.62% |
| 2016 Q2 | 70.87 Million CNY | 90.66% |
| 2016 Q1 | 37.17 Million CNY | 23.31% |
| 2015 Q1 | 7.82 Million CNY | -67.08% |
| 2015 Q3 | 35.99 Million CNY | 24.67% |
| 2015 FY | - CNY | 66.53% |
| 2015 Q4 | 30.14 Million CNY | -16.27% |
| 2015 Q2 | 28.87 Million CNY | 269.03% |
| 2014 Q4 | 23.76 Million CNY | 1086.2% |
| 2014 FY | - CNY | 25.51% |
| 2014 Q1 | 17.43 Million CNY | -50.0% |
| 2014 Q2 | 26.71 Million CNY | 53.21% |
| 2014 Q3 | 2 Million CNY | -92.5% |
| 2013 Q4 | 34.88 Million CNY | 984.55% |
| 2013 FY | - CNY | -37.53% |
| 2013 Q1 | 11.12 Million CNY | -75.78% |
| 2013 Q2 | 16.13 Million CNY | 44.96% |
| 2013 Q3 | 3.21 Million CNY | -80.06% |
| 2012 FY | - CNY | 3.33% |
| 2012 Q3 | 18.26 Million CNY | -21.07% |
| 2012 Q1 | 20.52 Million CNY | -44.01% |
| 2012 Q4 | 45.94 Million CNY | 151.51% |
| 2012 Q2 | 23.14 Million CNY | 12.73% |
| 2011 Q3 | 8.69 Million CNY | -78.37% |
| 2011 Q4 | 36.66 Million CNY | 321.9% |
| 2011 Q2 | 40.18 Million CNY | -3.88% |
| 2011 FY | - CNY | -17.99% |
| 2011 Q1 | 41.8 Million CNY | 14.49% |
| 2010 Q2 | 37.22 Million CNY | -5.6% |
| 2010 Q1 | 39.43 Million CNY | 0.0% |
| 2010 Q4 | 36.51 Million CNY | 2.05% |
| 2010 Q3 | 35.78 Million CNY | -3.87% |
| 2010 FY | - CNY | 32.74% |
| 2009 FY | - CNY | 86.24% |
| 2008 FY | - CNY | 390.64% |
| 2007 FY | - CNY | 0.0% |